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Background: Prostate cancer shows considerable heterogeneity in disease progression and we propose that markers expressed
in tumour stroma may be reliable predictors of aggressive tumour subtypes.
Methods: We have used Kaplan–Meier, univariate and multivariate analysis to correlate the expression of Asporin (ASPN) mRNA
and protein with prostate cancer progression in independent cohorts. We used immunohistochemistry and H scoring to
document stromal localisation of ASPN in a tissue microarray and mouse prostate cancer model, and correlated expression with
reactive stroma, defined using Masson Trichrome staining. We used cell cultures of primary prostate cancer fibroblasts treated
with serum-free conditioned media from prostate cancer cell lines to examine regulation of ASPN mRNA in tumour stromal cells.
Results: We observed increased expression of ASPN mRNA in a data set derived from benign vs tumour microdissected tissue,
and a correlation with biochemical recurrence using Kaplan–Meier and Cox proportional hazard analysis. ASPN protein localised
to tumour stroma and elevated expression of ASPN was correlated with decreased time to biochemical recurrence, in a cohort of
326 patients with a median follow up of 9.6 years. Univariate and multivariate analysis demonstrated that ASPN was correlated with
progression, as were Gleason score, and clinical stage. Additionally, ASPN expression correlated with the presence of reactive
stroma, suggesting that it may be a stromal marker expressed in response to the presence of tumour cells and particularly with
aggressive tumour subtypes. We observed expression of ASPN in the stroma of tumours induced by p53 inhibition in a mouse
model of prostate cancer, and correlation with neuroendocrine marker expression. Finally, we demonstrated that ASPN transcript
expression in normal and cancer fibroblasts was regulated by conditioned media derived from the PC3, but not LNCaP, prostate
cancer cell lines.
Conclusions: Our results suggest that ASPN is a stromally expressed biomarker that correlates with disease progression, and is
observed in reactive stroma. ASPN expression in stroma may be part of a stromal response to aggressive tumour subtypes.
Prostate cancer (PCa) is highly prevalent and represents 24%
of cancer diagnoses in Canadian men; in 2016, about 27 000
Canadian men will be diagnosed and 4100 will die from the
disease. The prevalence of PCa increases with age and there is a
large pool of indolent PCa which is best managed with active
surveillance. However, there is a limited ability to distinguish lethal
from indolent disease, resulting in many patients opting for
intervention and risking side effects and over-treatment. To
address this, several genomic, transcript and immunohistochemical
biomarkers have been assessed for their abilities to identify
progressive tumour subtypes and aid treatment choice between
intervention and surveillance (Martin, 2016). There is considerable
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inter- and intra- tumour heterogeneity which limits the efficacy of
predictive tests and most focus upon the ability to detect tumour
subclones associated with progression, which may be present at
low frequency in biopsy samples. We have focussed upon the
possibility that tumour stroma may exhibit markers expressed in
response to aggressive tumour subclones, which may help to
distinguish these from indolent tumour subtypes.
Cancer associated fibroblasts (CAFs) play a key role in
tumourigenesis by regulating tumour cell proliferation and
invasion, via mechanisms including growth factors, cytokines,
ECM stiffness, and immune cell trafficking (Olumi et al, 1999).
The histology of tumour stroma is predictive of disease progression
(Jia et al, 2011; Planche et al, 2011; Jia et al, 2012; Tian et al, 2015),
and particularly the presence of reactive stroma and collagen
deposition (Ayala et al, 2003; Yanagisawa et al, 2007). There are
several markers of CAFs such as FSP1, smooth muscle actin, CD90,
PDGFR, and FAP, which show partially overlapping expression,
though these are not predictive of disease progression. Gene
profiling studies have analysed prostate tumour stroma and CAFs,
with focus upon reactive stroma (Dakhova et al, 2009), CD90
positive stroma (Pascal et al, 2009), and primary CAFs (Orr et al,
2012) and all noted expression of ASPN mRNA in tumour
associated prostate stroma.
Asporin was identified among androgen responsive genes in
murine prostate development (Schaeffer et al, 2008), and using
immunohistochemistry we observed a localised expression pattern
of ASPN in subsets of human fetal prostate mesenchyme located
adjacent to developing prostatic buds (Orr et al, 2012). In tumour
stroma, ASPN was observed surrounding tumour cells suggesting a
possible role in progression. Interestingly, ASPN was expressed
in stroma with a partially overlapping pattern with stanniocalcin
1 (STC1), another molecule implicated in CAF regulation of
tumourigenesis (Pena et al, 2013). ASPN levels are elevated in the
blood of men with advanced prostate adenocarcinoma (Klee et al,
2012), and it is detectable in exosomes derived from saliva of
tumour-bearing mice (Lau et al, 2013).
Asporin, also known as periodontal ligament associated protein
(PLAP1) is a secreted small leucine rich proteoglycan with known
roles in ligament regulation and chondrogenesis via BMP and
TGBbeta pathways. It regulates BMP2, TGFb and FGF2 activity
through direct and indirect interactions (Kizawa et al, 2005;
Yamada et al, 2007; Tomoeda et al, 2008; Awata et al, 2015) and
also binds type II collagen (Kou et al, 2010). ASPN has been shown
to play a role in invasion in breast cancer cells (Simkova et al,
2016) and control the invasion of tumour cells and CAFs in
scirrhous type gastric cancer (Satoyoshi et al, 2014), both in vitro
and in vivo via the CD44-Rac1 pathway (Satoyoshi et al, 2014).
In prostate cancer, varying aspartic acid repeat length in the
N-terminus of ASPN is associated with prostate cancer progression
(Hurley et al, 2015). In contrast, in breast cancer, a lack of ASPN
expression in the stroma of triple negative cases is associated with
poor prognosis (Maris et al, 2015).
We have examined the role of ASPN in prostate cancer
progression, at the mRNA and protein level, in data sets with
clinical outcome. The association of ASPN with reactive stroma
was investigated, as well as expression of ASPN in the stroma of a
murine prostate cancer model. Finally, effects of tumour cell
factors upon ASPN expression in stromal cells were studied
in vitro.
MATERIALS AND METHODS
Human tissue samples. This study was approved by the Ethics
Board of the McGill University Health Centre. Written informed
consent was obtained from all the participants. We used a tissue
microarray (TMA) composed of 5 FFPE blocks containing samples
of 326 prostatectomy specimens of hormone naive patients from
1996 to 2007. Histopathologic review of all cases was performed by
one genitourinary pathologist (FB) using the modified Gleason
grading system (2015). Briefly, the benign and malignant regions of
all cases were identified and two 1.0mm cores were extracted from
the cancer area of the dominant nodule. One core of benign tissue
away from cancer was included for 20% of the cases. The TMA
was constructed by using a Beecher MT1 manual arrayer (Beecher
Instruments, Silver Spring, MD, USA). A commercial TMA was
purchased from USBioMAx.
Mouse TP53 prostate cancer model. PB-Cre/p53loxP/loxPRbloxP/loxP
mice develop low-grade PIN in the four lobes, but the aggressive,
castrate resistant metastatic tumours that develop in these mice arise
from the proximal region of the ducts near the urethra (Zhou et al,
2006, 2007). Tissue was collected from males between 5.5 and 7.7
months of age. Mice were maintained in the Cancer Research UK
Cambridge Institute Animal Facility. All animal procedures were
carried out in accordance with University of Cambridge and
Cancer Research UK guidelines under UK Home Office project
license 80/2435.
Statistical analysis. All statistical analyses were performed using R
(Team, R.D.C., 2011). Survival curves and Cox proportional hazard
were conducted with survival package (Therneau, 2015), survminer
(Kassambara, 2016) and survcomp (Schroder et al, 2011); the
P-values were computed using the log-rank test.
Immunohistochemistry. Immunostaining of ASPN on TMA was
performed using a rabbit anti-ASPN antibody (Sigma, HPA008435)
diluted 1 : 80. TMAs were de-paraffinised in xylene and hydrated in
ethanol and rinse under water. Endogenous peroxidase activity was
blocked for 30min with 3% H2O2. After a 3h block with IHC
Select (Millipore, Billeria, MA, USA), the primary antibody was used
overnight. Histofine Simple Stain MAX PO multi (Nichirei
BioSciences, Inc., Tokyo, Japan) was used as secondary antibody
and chromogenic detection was carried out using Simple Stain AEC
Solution (Nichirei BioSciences, Inc.). For immunostaining of null
mouse tissues, slides were pressure cooked in 10mM citric acid,
pH6.0 (Poly Scientific R&D), for 5min before staining. IHC was
performed using a rabbit anti-Aspn antibody (Genetex, Irvine, CA,
USA, GTX104790) diluted 1 : 1600 and anti-synaptophysin (BD
Biosciences, San Jose, CA, USA, BD611880) diluted 1 : 100. Images
were taken with an Aperio Slide Scanner (Leica, Wetzlar, Germany).
IHC data analysis. Asporin staining was assessed using the
staining H-score method (Bosman et al, 1992). H-score was
obtained by computing staining intensity (0–3) and the proportion
of stroma cells stained for each intensity (0–100) to give an H-score
between 0 and 300.
Reactive stroma was defined according to published criteria
(Yanagisawa et al, 2007) after staining with Masson’s Trichrome.
Cell lines. Normal adults prostate stromal cells, PrSC (Lonza),
primary culture of embryonic prostate fibroblast (EPF) (Orr et al,
2011), cancer-associated fibroblasts (CAF) (Orr et al, 2011),
WPMY-AR (Tanner et al, 2011), BHPrS (Franco et al, 2011),
PC-3 (ATCC), and LNCaP (ATCC) were grown in Dulbecco’s
modified Eagle medium GlutaMAX (Gibco, Waltham, MA, USA)
with 10% fetal bovine serum, without antibiotics.
For conditioned media, PC-3 and LNCaP cells (6 106) were
plated in 150 cm2 flasks and grown overnight. Cells were washed
with PBS and medium was replaced with serum free DMEM
GlutaMAX and incubated for 24 h. The medium was then collected,
centrifuged to remove cell debris and passed through a 0.22mm filter.
Stromal cells were plated in 60mm dishes and grown overnight. Cells
were washed twice in serum free DMEM and conditioned media was
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added for 24 h. RNA was extracted and cell proliferation was assessed
using CellTiter-Glo (Promega, Fichburg, WI, USA).
RNA extraction and quantitative real-time PCR. Total RNA was
extracted using the EZ-10 Spin Column Total RNA Minipreps
(BioBasic) following manufacturer’s instructions. Complementary
DNA was performed using High Capacity cDNA Reverse
Transcription (ABI) and qRT–PCR was performed on ABI 7500
Fast machine using SYBR Select Master Mix. Transcript abundance
was normalised to TBP expression. Primers used for TBP were
50-GGGGAGCTGTGATGTGAAGT-30 and 50-ACCAGGAAATA-
ACTCTGGCTCAT-30 and for ASPN were 50-TTGAAGGGGTGA-
CGGTGTTC-30 and 50-AGTGAAGCTCCAATAAAGTTGGT-30.
RESULTS
Expression of ASPN mRNA in patient cohorts. Increased
expression of ASPN mRNA has previously been observed in
cancer- associated fibroblasts by gene profiling studies (Dakhova
et al, 2009; Orr et al, 2012; Hurley et al, 2015), and some patient
cohorts (Hurley et al, 2015). We extended these observations
using a cohort with patient follow up to investigate correlation of
ASPN mRNA with biochemical recurrence (BCR) and other
clinical criteria. The association between ASPN expression, disease
progression, and recurrence was investigated using a recently
published prostate tumour profiling data (Mortensen et al, 2015)
derived from 36 microdissected tumour tissues with 14 patient
matched benign tissues. In the Mortensen data set tumour samples
showed a 1.3-fold increase of ASPN levels compared to patient
matched benign tissue (Figure 1A). Kaplan–Meier survival analysis
showed that patients with elevated levels of ASPN had a higher rate
of biochemical recurrence P¼ 0.0011 (Figure 1B). In univariate
and multivariate Cox hazards ratio analysis (Table 1A) ASPN
showed a significant association with biochemical recurrence
(HR¼ 2.16; P¼ 0.003; HR 2.23; P¼ 0.009). Other parameters such
as Gleason score, stage, and positive margins were also associated
with BCR (Table 1A). Overall, these data suggest that ASPN
mRNA levels correlated with increased probability of disease
progression in the Mortensen data set similar to that observed in
other data sets (Hurley et al, 2015).
Immunohistochemical analysis of ASPN in prostatectomy
tissues. We next examined the distribution of ASPN protein
using immunohistochemistry in order to define distribution within
tumour stroma of patient samples, and to examine association of
ASPN with clinical parameters. We performed immunohistochem-
istry using a TMA of prostate cancer tissue from a cohort of 326
patients who underwent radical prostatectomy. Clinico-pathologi-
cal characteristics of the patient cohort are listed in Supplementary
Table S1. Median age was 61 (range 43–73), median follow up was
9.6 years (range 0–20.8) and the percentage of patients showing
BCR was 25% (81). Asporin was localised using an antibody
validated in several independent studies (www.proteinatlas.org,
(Hurley et al, 2015; Maris et al, 2015; Satoyoshi et al, 2014;
Simkova et al, 2016). After immunohistochemistry, ASPN staining
was assessed using the H-score method which involved computing
staining intensity (0 to 3) and the proportion of stroma stained (0–
100) to give an H-score between 0 and 300. Most patient samples
consisted of duplicate cores and each core was examined by two
individuals and H-scores determined. The H-scores from duplicate
spots were averaged prior to analysis. Asporin staining was evident
in tumour stroma with a broad range of staining intensity and
extent, examples of H-score 0, 100, 200, and 300 are shown
(Figure 2A, high magnification shown in Supplementary Figure 1).
240 patients had an H-score between 0–100, 46 patients between
101–150, 23 patients between 151–200, 7 patients between 201–250
and 4 patients higher than 251. H-score of benign samples was less
than 30 for 91% of the samples, confirming that ASPN was low or
absent in normal prostate tissue, and consistent with lower ASPN
mRNA levels in benign tissue (Figure 1A).
We observed a correlation between increased H-score and
biochemical recurrence; patients with an H-score above 150
showed a 41% biochemical recurrence rate compared to 22%
among the remainder (P¼ 0.0077; Figure 2B). Univariate and
multivariate analysis of ASPN H-score in the McGill cohort
showed hazards ratios of 2.16 (P¼ 0.009) and 1.77 (P¼ 0.062) for
BCR (Table 1B), supporting the association of ASPN with
progression. We next examined the expression of ASPN within
patients with Gleason score of 7; this showed that those patients
positive for ASPN showed more rapid BCR than those who did not
(P¼ 0.0012; Figure 2C). Univariate and multivariate analysis
showed hazards ratios of 2.52 (P¼ 0.002) and 2.30 (P¼ 0.016)
for ASPN and BCR within the Gleason 7 subgroup (Table 1C).
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Figure 1. Correlation of ASPN mRNA with BCR in the prostate cancer patient cohort described by Mortensen et al (2015). (A) A significant
increase in ASPN transcripts was observed in tumour vs patient matched benign samples; mean ASPNmRNA levels of 7.0 in tumour samples vs 5.3
in benign samples (t-test, Po0.001). (B) Kaplan–Meier analysis correlated higher ASPN transcript levels with shorter time to biochemical recurrence
(P¼0.0011) in the Mortensen et al (2015) data set. The lower panel shows the number of patients at risk of BCR during 80 months of follow up.
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Asporin H-score was not associated with BCR in Gleason 3þ 4
patients (P¼ 0.18), in contrast to Gleason 4þ 3 samples where
there was a correlation with BCR (P¼ 0.026; Supplementary
Figure 2A and B). Similar results from univariate and multi-
variate analysis using patients with Gleason 6 and Gleason 7
(Supplementary Table S3) show the prognostic potential of ASPN
in Gleason sub-group where the need is biggest. The prognostic
value of ASPN in Gleason score of 7 was further evident using
C-statistics in comparison with pathological Gleason score or the
risk group. Risk group was defined by National Comprehensive
Cancer Network but here we used Gleason score at surgery instead
of biopsy Gleason grade. Low risk patients have a prostate specific
antigen (PSA) less than 10 ngml 1, Gleason score less than 7 and
stage less than T2a. Intermediate risk patients have a PSA between
Table 1B. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox
analysis of ASPN H-score in the complete McGill TMA
Univariate analysis Multivariate analysis
N (n) HR 95% CI P-value P-valuea P-valueb HR 95% CI P-value
ASPN 302 (78) 2.16 1.21–3.85 0.009 0.013 0.063 1.77 0.97–3.22 0.062
Age 294 (78) 1.02 0.98–1.06 0.411 0.411 1.000 0.99 0.95–1.03 0.638
Gleason score 302 (78) 23.59 3.28–169.7 0.002 0.004 0.014 16.70 2.28–122.2 0.006
Stage 302 (78) 3.11 1.98–4.88 7.76E07 5.40E06 5.40E06 1.77 1.06–2.98 0.030
PSA 302 (78) 1.03 1.00–1.05 0.015 0.018 0.105 1.00 0.97–1.02 0.808
SM 302 (78) 2.11 1.34–3.03 0.001 0.002 0.007 1.25 0.76–2.06 0.383
SV 302 (78) 3.57 1.88–6.79 1.04E04 3.64E04 7.28E04 1.98 0.98–4.00 7.44E05
Abbreviations: ASPN¼ asporin; BCR¼biochemical recurrence; CI¼ confidence interval; FDR¼ false discovery rate; HR¼ hazards ratio; PSA=prostate specific antigen; SM=surgical margin;
SV=seminal vesicle; TMA¼ tissue microarray. Cox proportional hazards ratio of ASPN H-score in the McGill TMA cohort. Univariate and multivariate Cox analysis of ASPN staining and clinical
variables in McGill cohort. ASPN H-score of 4150 showed a hazards ratio of 2.16 (P¼ 0.009) in univariate and 1.77 (P¼ 0.062) in multivariate analysis.
aFDR-adjusted P-value.
bBonferroni adjusted P-value. Bold indicates statistically significant values.
Table 1A. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox
analysis of ASPN mRNA and BCR in the Mortensen et al data set
Univariate analysis Multivariate analysis
N (n) HR 95% CI P-value HR 95% CI P-value
ASPN 36 (22) 2.16 1.30–3.59 0.003 2.23 1.32–4.66 0.009
Gleason score 36 (22) 1.75 1.19–2.58 0.005 1.44 0.77–2.60 0.228
PSA 36 (22) 1.07 1.03–1.12 0.001 1.08 1.02–1.14 0.005
Stage 33 (22) 4.21 1.60–11.08 0.004 0.76 0.14–4.27 0.759
Margin 36 (22) 3.70 1.51–9.03 0.004 2.39 0.57–10.04 0.236
Age 36 (22) 0.99 0.91–1.08 0.842 0.95 0.86–1.05 0.295
Abbreviations: ASPN¼ asporin; BCR¼biochemical recurrence; CI¼ confidence interval; HR¼ hazards ratio; PSA=prostate specific antigen; TMA¼ tissue microarray. Cox proportional hazards
ratio analysis showed that ASPNmRNA was predictive of BCR in both univariate (hazards ratio 2.16, P¼ 0.003) and multivariate analysis (hazards ratio 2.23, P¼ 0.009), in the Mortensen et al data
set derived from microdissected normal and tumour tissue. ASPN mRNA showed a larger hazards ratio than Gleason grade in this data set. Bold indicates statistically significant values.
Table 1C. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox
analysis of ASPN H-score in patients with Gleason 7 from the McGill TMA
Univariate analysis Multivariate analysis
N (n) HR 95% CI P-value P-valuea P-valueb HR 95% CI P-value
ASPN 208 (62) 2.52 1.46–5.42 0.002 0.004 0.014 2.30 1.17–4.55 0.016
Age 205 (62) 1.00 0.95–1.04 0.916 0.916 1.000 0.98 0.94–1.03 0.434
Gleason
score
208 (62) 2.60 1.58–4.30 1.80E04 0.001 0.001 2.15 1.22–3.79 0.008
Stage 208 (62) 2.16 1.31–3.56 0.002 0.004 0.014 1.38 0.76–2.52 0.294
PSA 208 (62) 1.03 1.00–1.06 0.060 0.084 0.420 1.00 0.97–1.03 0.956
SM 208 (62) 1.42 0.85–2.39 0.179 0.209 1.000 1.09 0.61–1.93 0.776
SV 208 (62) 3.43 1.55–7.56 0.002 0.004 0.014 2.89 0.89–5.89 0.087
Abbreviations: ASPN¼ asporin; BCR¼biochemical recurrence; CI¼ confidence interval; FDR¼ false discovery rate; HR¼ hazards ratio; PSA=prostate specific antigen; SM=surgical margin;
SV=seminal vesicle; TMA¼ tissue microarray. Univariate and multivariate Cox analysis of ASPN staining in the McGill TMA cohort subset of patients with a Gleason 7 score. ASPN H-score of
4150 showed a hazards ratio of 2.52 (P¼ 0.002) in univariate and 2.30 (P¼ 0.016) in multivariate analysis.
aFDR-adjusted P-value.
bBonferroni adjusted P-value. Bold indicates statistically significant values.
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10 and 20ngml 1 and/or Gleason score of 7 and/or a T-stage T2b
or T2c. High risk patients have a PSA greater than 20 ngml 1 and/
or Gleason score between 8 and 10 and/or a T3 stage. ASPN
performed better (C-index 0.74, P¼ 3.44E 04) than either risk group
alone (C-index 0.68, P¼ 0.002) or Gleason score alone (C-index 0.72,
P¼ 2.36E 05). Whereas ASPN improved prognostic capability
when combined with either risk group (C-index 0.70, P¼ 2.53E 05)
or Gleason score (C-index 0.72, P¼ 1.33E 06; Supplementary
Table S2A). Furthermore, multivariate Cox proportional hazard
analysis showed that ASPN together with risk group had
statistically significant improved prognostic ability over using risk
group alone (P¼ 0.010). ASPN together with Gleason score also
improved prognostic ability over Gleason score alone (P¼ 0.021;
Supplementary Table S2B). These finding demonstrate the
independent prognostic value of ASPN in patients with a Gleason
score of 7. In the complete McGill cohort ASPN had also a good
prognostic value (C-index 0.68, P¼ 0.007) as well as risk group
(C-index 0.76, P¼ 1.04E-13) and Gleason score (C-index 0.97,
P¼ 8.21E-45). But ASPN did not improve prognostic capability
when combined with either risk group (C-index 0.75, P¼ 4.98E-15)
or Gleason score (C-index 0.84, P¼ 3.63E-27) (Supplementary
Table S2C). Cox proportional hazard modelling of ASPN H-score
in the complete McGill TMA showed a significant association
between ASPN and Gleason Grade (Supplementary Table S2D). To
examine a correlation between ASPN H-score and multiple
Gleason grades, we plotted H-scores against Gleason 6, 7, and
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Figure 2. Correlation of ASPN protein expression with BCR using IHC staining of a TMA with patient outcome data. Immunohistochemistry
staining of ASPN was undertaken on the McGill cohort of 326 patients with follow up; outcome data and clinico-pathological details are listed in
Supplementary Table S1. Asporin staining (brown/red) was observed in stroma and showed peri-tumoural distribution with varying intensity and
extent. (A) Representative images of ASPN staining quantified by H-score, with examples of H-scores 0, 100, 200, and 300. Scale bar is 400mm.
H-score combines the staining extent and intensity observed, and was scored by two individuals. (B) Kaplan–Meier analysis of ASPN H-score
demonstrated that patients with an H-score over 150 showed increased BCR (P¼0.0077). (C) High ASPN (H-score4150) was correlated with
increased progression (BCR) in the subset of patients with Gleason grade 7 (P¼0.0012) relative to patients with low ASPN (H-scorep150). Panel D:
H-score values for ASPN staining and Gleason grade. There was low ASPN staining in benign tissue, and increased ASPN staining in Gleason
grades 6, 7, and 8þ 9 (ANOVA followed by Tukey multiple comparison, *Po0.05, **Po0.01 and ***Po0.001). Mean ASPN levels in benign
H-score¼ 9.5, Gleason 6 H-score¼ 55.9, Gleason 7 H-score¼ 71.0, Gleason 8þ 9 H-score¼97.4.
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8þ 9 combined (Figure 2D). This showed that higher Gleason
scores showed statistically significant increased ASPN expression
(benign 9.5, Gleason 6 55.8, Gleason 7 71.0, and Gleason
8þ 9 97.4).
Hurley et al (2015) observed association of ASPN with
metastatic disease in some but not all prostate cancer cohorts.
A comparison of ASPN and the presence of metastatic disease in
the McGill cohort showed no significant correlation (Supple-
mentary Figure 2C) though the number of patients with metastatic
disease was low. Consequently, we used metastatic samples in two
commercially sourced TMAs to examine association of ASPN with
metastasis. These TMAs consisted of 24 cores (6 patients) and 26
cores (13 patients), where 12 patients had distant metastasis
defined by their TNM stage. Staining intensity was examined and
scored on a scale of 0–3. There was low staining observed in cores
from a patient with T2N0M0 tumour stage when compared to
strong staining observed in a patient with T3N0M1b tumour stage
(Supplementary Figure 3). Within this small number of patients
(12), a comparison of all cores showed a more intense staining for
patients with metastasis than those without (Supplementary
Figure 3), in contrast to the lack of association in our McGill
cohort (Supplementary Figure 2C).
ASPN and reactive stroma. Since we, and others, had observed a
correlation of ASPN mRNA and protein with BCR we chose to
examine whether ASPN expression might correlate with reactive
stroma. Reactive stroma has been associated with progression and
prostate cancer specific mortality (Ayala et al, 2003; Yanagisawa
et al, 2007) and has been defined using Masson trichrome staining
followed by assignation to reactive stroma grade (RSG) 0, 1, 2,
and 3. RSG0 and 3 are associated with poor outcome, and we
speculated that ASPN might be a marker of reactive stroma. To test
whether ASPN was associated with reactive stroma, we stained the
McGill TMA with Masson’s trichrome, and identified samples with
low or high levels of reactive stroma (RSG1þ 2 vs RSG0þ 3).
These samples had been H-scored for ASPN and thus we could
correlate this with the presence or absence of reactive stroma.
Trichrome staining and examples of RSG 0, 1, 2, and 3 are
shown in Figure 3A (high-magnification images are shown in
Supplementary Figure S4) and were defined using the criteria
described in (Ayala et al, 2003; Yanagisawa et al, 2007). RSG1 and
2 were combined, grouping together samples with o50% of the
stroma positive for reactive stroma, and defined as low RSG. RSG0
samples were defined as having a very low stromal content, because
of high tumour cellularity, where the little stroma present was
reactive (ie 100% reactive stroma, but small stromal proportion).
RSG0 was combined with RSG3, comprised of samples with high
stromal content and 450% reactive stroma–thus the combination
of samples with RSG0 and RSG3 were defined as high reactive
stroma. We observed that samples with a high reactive stromal
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Figure 3. Co-identification of ASPN and reactive stromal histology. After IHC staining with ASPN and image storage, we stripped the TMA and
performed Masson’s trichrome staining to identify areas of reactive stroma. Low reactive stroma was scored as RSG1 and 2 while high reactive
stroma was RSG0 and RSG3 (Ayala et al, 2003; Yanagisawa et al, 2007). (A) Representative images of samples graded as reactive stroma 1, 2, (low)
and 0, and 3 (high) using Masson’s trichrome. (B) Graph of patients showing ASPN staining and reactive stroma; ASPN staining was observed in
patients with or without reactive stroma and there was evidence of elevated ASPN staining (H-score) and high reactive stroma (Low reactive stroma
samples had a mean H-score of 61.5 while high reactive stroma samples showed an ASPN H-score of 94.3, t-test P¼0.001). (C) Kaplan–Meier
curve of progression among patients with no reactive stroma and low ASPN H-score (black), high reactive stroma and high ASPN (red), and
patients showing either reactive stroma or ASPN (blue). Comparison among the three groups showed that samples positive for both reactive
stroma and ASPN was predictive of progression as well as samples showing either high reactive stroma or ASPN (Po0.0001). There was no
statistically significant difference between the double positive and single positive samples (P¼0.32).
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score also showed elevated ASPN H-scores (mean H-score 94.3),
when compared to low reactive stromal samples (mean H-score
61.5, P¼ 0.001) (Figure 3B). However, there were clearly some low
reactive stroma samples with high levels of ASPN staining, as well
as the converse. To investigate the relevance of reactive stroma and
ASPN to disease progression, we performed Kaplan–Meier analysis
of RSG and ASPN. We observed that patients with low ASPN and
low RSG fared better than those with high ASPN and high RSG
(Po0.0001). This analysis also showed that patients that were
either ASPN positive or RSG positive progressed more rapidly than
those with low RSG/ASPN, and were not significantly different
from those patients with both reactive stroma and high ASPN H-
score (Figure 3C). Individual samples showing the range of ASPN
and reactive stroma are shown in Supplementary Figure 5.
Expression of ASPN in stroma of mouse p53 Null model prostate
tumours. The correlation between stromal expression of ASPN and
progression suggested that expression of ASPN within the stroma
may be a response to aggressive tumour types or subclones. To
investigate this further, we examined ASPN expression using another
antibody (antibody validation Supplementary Figure S6) in a model of
aggressive prostate cancer induced by deletion of TP53 in prostate
epithelia (Zhou et al, 2006, 2007); to determine whether ASPN was
present in tumour cells and/or tumour stroma. Tumours in this
model system showed very low stromal content, however we observed
ASPN staining within the tumour stroma that was present
(Figure 4A–D). The patchy distribution of ASPN staining was
reminiscent of that observed in patient tumours (Figure 2A) as well as
showing similarity to stroma with RSG0 (Figure 3A). This mouse
model often develops neuroendocrine prostate cancer, staining against
synaptophysin confirmed that (Figure 4E and F) suggesting that
ASPN is associated with aggressive prostate cancer.
Regulation of ASPN mRNA in Fibroblasts by tumour cell
conditioned media. To examine the mechanisms involved in the
increased expression of ASPN in peri-tumoural stroma, we tested
the effects of cancer cell conditioned media upon the expression of
ASPN mRNA in prostate fibroblasts. Our hypothesis was that
ASPN might be upregulated by factors secreted from tumour cells,
as observed in gastric cancer (Satoyoshi et al, 2014). We prepared
serum-free conditioned media from two different prostate cancer
cell lines (PC-3 and LNCaP) and added these to fetal prostate
fibroblasts (EPF), primary normal prostate stroma (PrSC),
and three CAF isolates. After 24 h exposure to the serum-free
conditioned medium stromal cells were collected and ASPN
transcript levels measured by qRT–PCR (Figure 5). Normal
fibroblasts, both embryonic (EPF) and adult (PrSC), showed an
increase of ASPN mRNA when grown with conditioned media
from PC-3 cells while conditioned media from LNCaP did not
induce ASPN mRNA after 24 h (Figure 5). CAF derived from three
different patients were used and two of these showed increased
ASPN transcript levels in response to PC-3 CM. LNCaP CM
showed little or no effect and we propose that PC-3 cells express
factors that may mimic aggressive tumour subtypes. A cell
proliferation assay showed no difference in growth rate between
fibroblasts grown with or without CM (data not shown), suggesting
that effects upon ASPN levels were not due to changes in
proliferation.
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Figure 4. Expression of ASPN in the murine TP53 prostate cancer model. Asporin was localised by immunohistochemistry in the mouse probasin
driven TP53 prostate cancer model to determine whether there was expression in stromal cells and/or tumour cells. Prostate tumours from prostate
specific p53 knockout mice showed ASPN staining in the stromal compartment (low magnification, A and C; high magnification, B and D). Tumours
showed few stromal cells, though many of those present were positive for ASPN. IHC controls without primary antibody are insert in A and B. Left
panels  10 magnification and right panels at  40 magnification. Synaptophysin staining is shown in E and F.
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DISCUSSION
We show that increased levels of ASPN mRNA or protein are
significantly associated with biochemical recurrence in prostate
cancer patients following radical prostatectomy, in the McGill
cohort and the Mortensen et al (2015) cohort. While the
Mortensen cohort was small (36 patients), we suggest that the
use of microdissected tissues is important for markers expressed in
stroma, as well as validation in independent data sets. Kaplan–
Meier analysis revealed a significant association of ASPN with
BCR. Univariate and multivariate analysis of stromal ASPN
expression showed ASPN as an independent prognostic factor,
and ASPN protein expression was associated with increasing
Gleason grade. Our results agree with others that have observed an
association of ASPN with prostate cancer (Hurley et al, 2015) and
this concordance supports the general conclusion that stromal
expression of ASPN is a predictive feature of aggressive prostate
cancer subtypes. Hurley et al (2015) also noted an association of
ASPN with metastatic recurrence in Mayo Clinic cohort. We were
unable to address this in the McGill cohort due to a low rate (5%,
15 cases) of metastasis, however we did observe an association of
ASPN with metastasis in a small commercially sourced TMAs.
Hurley et al (2015) also noted that the length of aspartic acid (D)-
repeat domain in ASPN gene was associated with patient outcome.
Germline ASPN D13/14 (or any D14) was significantly associated
with metastatic recurrence following surgery while ASPN D13/13
was associated with a reduced risk of metastatic progression.
Germline ASPN D13/14 was also associated with biochemical
recurrence following surgery but when controlled for pre-surgical
variables in multivariable Cox regression analysis the hazards ratio
was not significant.
The association between ASPN and metastatic recurrence in
prostate cancer may be due to increased co-invasion of CAFs and
cancer cells (Gaggioli et al, 2007) and as established in gastric
cancer. Asporin activates Rac1 via an interaction with CD44 and
promotes invasion of CAFs and may also transactivate Rac1 in
cancer cells to stimulate their invasion (Satoyoshi et al, 2014).
Fibroblasts overexpressing ASPN (D14 variant) mixed with PC-3
cells and then grafted into murine prostates showed a higher
number of metastases to distant lymph nodes and other organs
including lung, liver and pancreas than control cells (Hurley et al,
2015). It was previously revealed that ASPN regulates BMP2 and
TGFb1 activity through direct and indirect interactions (Kizawa
et al, 2005; Yamada et al, 2007; Tomoeda et al, 2008). Among its
roles TGFb serves as a tumour suppressor by inducing cell cycle
arrest and or apoptosis (Wikstrom et al, 2001). Asporin negatively
regulates TGFb and this leads to an increase in cell proliferation
and a decrease in apoptosis. More recently it has been shown that
ASPN regulates TLR2- and TLR4-induced inflammatory responses
(Yamaba et al, 2015) and also positively regulates FGF2 activity
(Awata et al, 2015). FGF2 is increased in prostate cancer compared
to normal prostate tissue, and increased FGF2 is localised to the
tumour stroma. FGF2 may induce matrix metalloproteinases
(Miyake et al, 1997; Linder et al, 1998) which could enhance
tissue invasion by the tumour cells in vivo.
It is now well accepted that the tumour microenvironment plays
an important role in tumour progression (Quail and Joyce, 2013).
Recent studies have identified other stromal markers associated
with prostate cancer progression. Patients with high expression of
VEGF-A in stroma and/or high expression of VEGFR-2 in stroma
had higher rates of biochemical failure. Patients with high stromal
expression of VEGFR-2 had a significantly worse outcome
regarding clinical failure defined as a palpable tumour recurrence
in the prostate bed or metastasis (Nordby et al, 2015). Similarly,
strong MCT4 density in stroma was a significant prognosticator of
lower biochemical failure-free survival. However in multivariate
analysis MTC4 expression alone had no individual independent
prognostic effect on BCR when adjusting for acknowledged and
significant clinicopathological variables. But coexpression of MTC1
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Figure 5. The effect of conditioned media from prostate cancer cell lines upon ASPN expression levels in fibroblasts. Serum-free conditioned
media was prepared from PC-3 and LNCaP cells, and added to fetal prostate fibroblasts (EPF), primary prostate stromal cells (PrSC), and 3 isolates
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in tumour and MCT4 in stroma was independently and
significantly associated with BCR (Andersen et al, 2015). Periostin,
an extracellular matrix protein has been reported to be able to
distinguish prostate cancer from BPH and PIN and correlates with
increasing Gleason score (Tian et al, 2015). Taken together, it
appears that stromal markers are correlated with BCR, but that
better performing markers are required for patient stratification
and treatment choice.
In gastric cancer, expression of ASPN in fibroblasts was
increased upon incubation of the cells in conditioned medium
from gastric epithelial cells (Satoyoshi et al, 2014). We observed
a similar increase in expression of ASPN mRNA in prostate
fibroblasts following incubation with conditioned media with the
prostate cancer PC-3 cell line. Normal fibroblasts showed increased
levels of ASPN but this was only observed in 2 out of 3 CAF lines.
This may reflect CAF heterogeneity, which is well documented. We
observed that CM from LNCaP cells was unable to induce ASPN
mRNA levels suggesting that there may be PC-3 or tumour specific
regulators of stromal ASPN expression. It supports the hypothesis
that expression of ASPN in tumour stroma is a response to
aggressive tumour subtypes. This is further supported by our
observation of Aspn expression in the stroma of the TP53 mouse
model of prostate cancer.
In conclusion, we demonstrated that ASPN expression is
correlated with disease progression in prostate cancer using a
large cohort, consistent with recent studies. Experimentally, we
observed expression of Aspn in stroma in a mouse prostate cancer
model, and we demonstrated that cancer cell lines could increase
ASPN expression in fibroblasts. This suggests that ASPN is
expressed in response to tumour cell derived factors in patients and
that a stromal response to aggressive tumour subclones may be of
prognostic value.
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